U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07181369) titled 'A Phase 1 Study of GTX-B001 in Healthy Subjets and Patients With Cold Urticaria' on Sept. 12.
Brief Summary: This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with cold urticaria.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Subjects
Cold Urticaria
Intervention:
DRUG: GTX-B001
Single infusion of one of up to five dosages of GTX-B001
DRUG: Normal Saline
Single infusion of normal saline
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Granular Therapeutics Limited
Disclaimer: Curated by HT Syndication....